PARP Inhibitor Lynparza Effective in Men with BRCAMutant Prostate Cancer
PARP Inhibitor - Lynparza Effective in Men with BRCA-Mutant Prostate Cancer
Men with prostate cancer have genomic defects that can be targeted with Lynparza and should undergo genomic testing.
More From BioPortfolio on "PARP Inhibitor - Lynparza Effective in Men with BRCA-Mutant Prostate Cancer"